Frontlight ResearchEarly access
TerminatedPhase 1/2
A Trial for Treatment of Cancer Patients With Multiple Brain Metastases Undergoing Whole-Brain Radiotherapy
Key facts
- Who runs it
- BioMimetix JV, LLC
- Where
- Detroit, Durham, Lexington, and Seattle, United StatesSee the 4 sites
- Trial code
- Status
- Terminated
- Phase
- Phase 1/2
- People taking part
- 35 people enrolled
- Started
- 4 Oct 2018
- Ended
- 15 Apr 2024
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- BMX-001
- Whole Brain Radiation Therapy
- Record updated
- 18 April 2024
- Why it stopped
- Cessation of grant funding
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 26 criteriaShow less
Who can take part
- Subjects must have histologically confirmed diagnosis of a non-small cell lung cancer, breast cancer, melanoma or renal cell cancer primary
- Subjects must have >5 contrast-enhancing lesions, never previously treated with SRS and/or surgical resection, on a contrast-enhanced T1-weighted brain MRI performed within two weeks of enrollment, with at least one lesion >0.5cm in greatest dimension
- Physical examination by a radiation oncologist or medical oncologist within 14 days of the start of WBRT
- Plan to be treated with WBRT to a dose of 30 Gy in 10 fractions
- Age * 18 years
- Karnofsky Performance Status (KPS) ≥ 70
- Hemoglobin ≥ 9.0 g/dl, ANC ≥ 1,500 cells/*l, platelets ≥ 125,000 cells/*l
- Serum creatinine ≤ 1.5 mg/dl, serum SGOT and bilirubin ≤ 1.5 times upper limit of normal
- Signed informed consent approved by the Institutional Review Board
- If sexually active, patients must agree to use appropriate contraceptive measures for the duration of the study and for 6 months afterwards as stated in the informed consent
- Able to provide study specific informed consent
- Willing to follow study procedures, complete QOL questionnaires and neurocognitive testing as described in the protocol
- Negative serum pregnancy test for women of child bearing potential within 48 hours of first dose of BMX
Who cannot take part
- Active infection requiring IV antibiotics 7 days before enrollment
- Requirement for concurrent treatment with nitrates or other drugs that may, in the judgment of the treating investigator, create a risk for a precipitous decrease in blood pressure
- Subjects receiving prohibited medications listed in Section 6.4.2 of this protocol are not eligible. Subjects who can safely stop taking a prohibited medication at least 7 days prior to the first dose of BMX may participate at the discretion of the treating physician
- Prior surgical resection for brain metastases and/or stereotactic radiosurgery for up to 5 brain metastases in total are permitted if performed at least 1 month prior to planned WBRT under this protocol
- Prior whole brain radiation therapy
- Hypertension requiring 3 or more anti-hypertensive medications to control
- History of syncope within the last 6 months
- Known hypersensitivity to compounds of similar chemical composition to BMX-001
- Patients with diffuse leptomeningeal disease (carcinomatous meningitis)
- A marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration of a QTc interval >480 milliseconds (ms) (CTCAE grade 1)
- A history of additional risk factors for TdP (e.g., congestive heart failure, hypokalemia, known family history of Long QT Syndrome)
- Pregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception; this exclusion is necessary because the treatment involved in this study may be significantly teratogenic
- Women who are breast feeding
Where in United States
- Henry Ford HospitalDetroit, United States
- Duke Cancer InstituteDurham, United States
- University of KentuckyLexington, United States
- University of WashingtonSeattle, United States
About the trial
What the trial wants to find out
This protocol is for a lead-in safety study of 5 patients followed by a randomized Phase 2 clinical trial of BMX-001, a new class of pharmaceutical, in 64 patients with multiple brain metastases (MBM) undergoing whole brain radiation therapy (WBRT). Preliminary studies have demonstrated that BMX-001 provides protection of normal tissues from radiation-induced injury and augments tumor growth inhibition.
The 2 groups in the trial
- WBRT + BMX-001Existing treatment, for comparison
Whole brain radiation therapy in combination with BMX-001 (subcutaneous injection of 28 mg loading dose, followed by subsequent 14 mg twice per week for 2 weeks).
Treatment: BMX-001 and Whole Brain Radiation Therapy
- Whole Brain Radiation TherapyNo study treatment, for comparison
Whole brain radiation therapy per standard of care.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Safety Lead-In/Randomized Phase 2 Study of BMX-001 as a Therapeutic Agent for Treatment of Cancer Patients With Multiple Brain Metastases Undergoing Whole-Brain Radiotherapy
- Record updated
- 18 April 2024